ALLO · NASDAQ
Allogene Therapeutics (ALLO) Stock Price & Fundamentals
Allogene Therapeutics (ALLO) closed at $1,218.71 on Oct 9, 2026, up 1.10% from the previous close of $1,205.45.
Share price, past year
1Y +22.22%Monthly closing prices
| Date | Close |
|---|---|
| Oct 9, 2026 | $1,218.71 |
| Sep 30, 2026 | $1,195.91 |
| Aug 31, 2026 | $1,217.36 |
| Jul 31, 2026 | $1,249.66 |
| Jun 30, 2026 | $1,218.45 |
| May 29, 2026 | $1,127.11 |
| Apr 30, 2026 | $1,103.36 |
| Mar 31, 2026 | $1,045.05 |
| Feb 27, 2026 | $1,070.65 |
| Jan 30, 2026 | $1,065.19 |
| Dec 31, 2025 | $1,059.04 |
| Nov 28, 2025 | $1,080.60 |
| Oct 31, 2025 | $990.23 |
Key statistics
- Market cap
- $420.88B
- P/E (TTM)
- —
- EPS (TTM)
- −$0.67
- Revenue (TTM)
- —
- Net income (TTM)
- −$165.49M
- Shares outstanding
- 345.3M
- Dividend yield
- —
- 52-week range
- $971.56 – $1,249.66
Allogene Therapeutics's market cap is $420.88B, based on a share price of $1,218.71 and 345.3M shares outstanding as of Jun 30, 2026.
Financials
Allogene Therapeutics reported revenue of $0.00 for fiscal 2025, down 100.00% from fiscal 2024.
Allogene Therapeutics reported a net loss of $190.89M in fiscal 2025.
Annual revenue
| Fiscal year | Revenue | Growth | Net income | Net margin | EPS (diluted) | Free cash flow |
|---|---|---|---|---|---|---|
| FY2025ended Dec 31, 2025 | $0.00 | −100.0% | −$190.89M | — | −$0.87 | −$149.63M |
| FY2024ended Dec 31, 2024 | $22.00K | −76.8% | −$257.59M | −1,170,863.6% | −$1.32 | −$200.99M |
| FY2023ended Dec 31, 2023 | $95.00K | −39.1% | −$327.27M | −344,489.5% | −$2.09 | −$239.25M |
| FY2022ended Dec 31, 2022 | $156.00K | −99.9% | −$340.41M | −218,214.1% | −$2.38 | −$225.71M |
| FY2021ended Dec 31, 2021 | $114.09M | — | −$182.05M | −159.6% | −$1.34 | −$206.26M |
| FY2020ended Dec 31, 2020 | $0.00 | — | −$316.38M | — | −$2.63 | −$181.05M |
| FY2019ended Dec 31, 2019 | $0.00 | — | −$184.59M | — | −$1.83 | −$188.14M |
| Quarter | Revenue | Net income | EPS (diluted) |
|---|---|---|---|
| Q2 FY2026ended Jun 30, 2026 | $4.64M | −$42.68M | −$0.13 |
| Q4 FY2025ended Dec 31, 2025 | $0.00 | −$38.81M | −$0.17 |
| Q3 FY2025ended Sep 30, 2025 | $0.00 | −$41.40M | −$0.19 |
| Q2 FY2025ended Jun 30, 2025 | $0.00 | −$50.94M | −$0.23 |
| Q1 FY2025ended Mar 31, 2025 | $0.00 | −$59.73M | −$0.28 |
| Q4 FY2024ended Dec 31, 2024 | $0.00 | −$59.94M | −$0.27 |
| Q3 FY2024ended Sep 30, 2024 | $0.00 | −$66.29M | −$0.32 |
| Q2 FY2024ended Jun 30, 2024 | $0.00 | — | — |
Company profile
- Name
- Allogene Therapeutics, Inc.
- Ticker
- ALLO
- Exchange
- NASDAQ
- Industry (SEC SIC)
- Biological Products, (No Diagnostic Substances)
- Headquarters
- 210 East Grand Avenue, South San Francisco, CA 94080
- Fiscal year ends
- December
- SEC CIK
- 0001737287
Recent SEC filings
- Sep 2, 2026
- Aug 12, 2026
- Aug 12, 2026
- Jun 22, 2026
- May 28, 2026
- May 13, 2026
- May 13, 2026
- Apr 15, 2026
Frequently asked questions
What is Allogene Therapeutics's stock price?
Allogene Therapeutics (ALLO) closed at $1,218.71 on Oct 9, 2026, up 1.10% from the previous close of $1,205.45.
What is Allogene Therapeutics's market cap?
Allogene Therapeutics's market cap is $420.88B, based on a share price of $1,218.71 and 345.3M shares outstanding as of Jun 30, 2026.
How much revenue does Allogene Therapeutics make?
Allogene Therapeutics reported revenue of $0.00 for fiscal 2025, down 100.00% from fiscal 2024.
Does Allogene Therapeutics pay a dividend?
Yes. Allogene Therapeutics declared $0.00 per share in dividends for fiscal 2025.
Sources and methodology
Fundamentals come from Allogene Therapeutics, Inc.'s filings with the SEC (EDGAR XBRL company facts). Fourth-quarter figures that companies don't report separately are calculated as the fiscal year minus the first three quarters. Trailing twelve-month (TTM) figures sum the latest four quarters. Prices are generated sample data for development. Last updated Oct 9, 2026. Data sources and disclosures